Short- versus long-course antibacterial therapy for community-acquired pneumonia : a meta-analysis (Q28291976)

4

Alexandros P Grammatikos

0 references

Dimitrios K. Matthaiou

Dimitrios K Matthaiou

Drosos E. Karageorgopoulos

2

0 references

Drosos E Karageorgopoulos

3

0 references

Matthew E. Falagas

6

Matthew E Falagas

0 references

George Dimopoulos

1

George Dimopoulos

0 references

Zoe Athanassa

5

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

Zoe Athanassa

0 references

language of work or name

English

0 references

publication date

2008

0 references

published in

Drugs

0 references

volume

68

0 references

issue

13

0 references

page(s)

1841-54

0 references

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200868130-00004

Compliance of German pediatric patients with oral antibiotic therapy: results of a nationwide survey

21 January 2018

1 reference

12 December 2020

Antibiotic noncompliance and waste in upper respiratory infections and acute diarrhea

1 reference

12 December 2020

Time course of symptom resolution in patients with community-acquired pneumonia

1 reference

12 December 2020

Length of antibiotic therapy in in-patients with primary pneumonias

1 reference

12 December 2020

Controlling the risk of spurious findings from meta-regression.

1 reference

12 December 2020

British Thoracic Society Guidelines for the Management of Community Acquired Pneumonia in Childhood

1 reference

12 December 2020

Metaanalysis of short course antibiotic treatment for group a streptococcal tonsillopharyngitis

1 reference

12 December 2020

Meta-analysis in clinical trials

1 reference

12 December 2020

Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia

1 reference

12 December 2020

High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm

1 reference

12 December 2020

Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis

1 reference

12 December 2020

Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double-blind study

1 reference

12 December 2020

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

1 reference

12 December 2020

Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia

1 reference

12 December 2020

Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients

1 reference

12 December 2020

Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines.

1 reference

12 December 2020

Assessing the quality of randomized controlled trials. Current issues and future directions

1 reference

12 December 2020

Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001-02.

1 reference

12 December 2020

Pan-European survey of patients' attitudes to antibiotics and antibiotic use

1 reference

12 December 2020

Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial

1 reference

12 December 2020

Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial

1 reference

12 December 2020

Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae.

1 reference

12 December 2020

Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study

1 reference

12 December 2020

Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial

1 reference

12 December 2020

Treatment of acute otitis media with a shortened course of antibiotics: a meta-analysis

1 reference

12 December 2020

Community-acquired pneumonia in children

1 reference

12 December 2020

Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial

1 reference

12 December 2020

Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial

1 reference

12 December 2020

What is heterogeneity and is it important?

1 reference

12 December 2020

Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study

1 reference

12 December 2020

Statistical aspects of the analysis of data from retrospective studies of disease

1 reference

12 December 2020

Early Switch From Intravenous to Oral Antibiotics and Early Hospital Discharge

1 reference

12 December 2020

Etiology of severe pneumonia in children in developing countries

1 reference

12 December 2020

Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study

1 reference

12 December 2020

Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study

1 reference

12 December 2020

Community-acquired pneumonia: the annual cost to the National Health Service in the UK

1 reference

12 December 2020

Respiratory syncytial virus infection in tropical and developing countries

1 reference

12 December 2020

Tissue-directed pharmacokinetics

1 reference

12 December 2020

The importance of quality of primary studies in producing unbiased systematic reviews

1 reference

12 December 2020

Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia

1 reference

12 December 2020

The cost of treating community-acquired pneumonia.

1 reference

12 December 2020

A prediction rule to identify low-risk patients with community-acquired pneumonia

1 reference

12 December 2020

Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland

1 reference

12 December 2020